Glecaprevir And Pibrentasvir has 39 known drug interactions based on U.S. FDA drug labeling data. Of these, 4 are contraindicated combinations that should be avoided entirely. 9 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Amlodipine And Atorvastatin, Atazanavir, Atorvaliq. Patients taking Glecaprevir And Pibrentasvir should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 39
- Contraindicated
- 4
- Major
- 9
- Moderate
- 1
Contraindicated (4)
- Glecaprevir And Pibrentasvir + Amlodipine And Atorvastatin— Avoid atorvastatin due to increased risk of myopathy and rhabdomyolysis.
- Glecaprevir And Pibrentasvir + Atazanavir— HIV-Antiviral Agents: Atazanavir ↑ glecaprevir ↑ pibrentasvir Coadministration is contraindicated due to increased risk …
- Glecaprevir And Pibrentasvir + Atorvaliq— Significantly increases atorvastatin plasma levels and risk of myopathy and rhabdomyolysis. Concomitant use is not recom…
- Glecaprevir And Pibrentasvir + Atorvastatin Calcium— Significantly increases atorvastatin plasma levels and increases myopathy/rhabdomyolysis risk. Concomitant use is not re…
Major (9)
- Glecaprevir And Pibrentasvir + Carbamazepine— May significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect.…
- Glecaprevir And Pibrentasvir + Desogestrel And Ethinyl Estradiol And Ethinyl Estradiol— Co-administration is not recommended due to potential for ALT elevations.
- Glecaprevir And Pibrentasvir + Efavirenz— May significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect.…
- Glecaprevir And Pibrentasvir + Norethindrone Acetate, Ethinyl Estradiol And Ferrous Fumarate— Not recommended due to potential for ALT elevations.
- Glecaprevir And Pibrentasvir + Norethindrone Acetate/Ethinyl Estradiol— Coadministration is not recommended due to potential for ALT elevations.
- Glecaprevir And Pibrentasvir + Phenytoin— May significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect.…
- Glecaprevir And Pibrentasvir + Rosuvastatin— Combination increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Glecaprevir And Pibrentasvir + Rosuvastatin Calcium— Increases rosuvastatin exposure. Limit rosuvastatin dose to 10 mg once daily.
- Glecaprevir And Pibrentasvir + St. John'S Wort— May significantly decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect.…
Moderate (1)
- Glecaprevir And Pibrentasvir + Warfarin— Clearance of HCV infection may alter hepatic function and impact INR. Frequent monitoring of INR and dose adjustments ma…